{"id":"glipizide-and-glargine","safety":{"commonSideEffects":[{"rate":"5–15","effect":"Hypoglycemia"},{"rate":"2–5","effect":"Weight gain"},{"rate":"2–4","effect":"Headache"},{"rate":"1–3","effect":"Dizziness"},{"rate":"1–2","effect":"Injection site reactions (glargine)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glipizide is a meglitinide that binds to ATP-sensitive potassium channels on beta cells, triggering insulin release in response to glucose. Glargine is a long-acting insulin analog that provides steady, basal insulin coverage over 24 hours. Together, they address both postprandial and fasting hyperglycemia in type 2 diabetes.","oneSentence":"Glipizide stimulates insulin secretion from pancreatic beta cells, while glargine provides long-acting basal insulin replacement to lower blood glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:05.805Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT01698775","phase":"PHASE3","title":"A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-02","conditions":"Type 2 Diabetes Mellitus","enrollment":213},{"nctId":"NCT00347100","phase":"PHASE4","title":"Insulin Glargine in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Diabetes Mellitus, Type 2","enrollment":387},{"nctId":"NCT00732524","phase":"PHASE4","title":"Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2004-09","conditions":"Type 2 Diabetes","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Insulin Lantus"],"phase":"marketed","status":"active","brandName":"Glipizide and Glargine","genericName":"Glipizide and Glargine","companyName":"Cook County Health","companyId":"cook-county-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glipizide stimulates insulin secretion from pancreatic beta cells, while glargine provides long-acting basal insulin replacement to lower blood glucose. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}